Seagen (SGEN) Stock Price
Seagen Price
Revenue has compounded at 36.0% per year over the past 19 years to 2.30 B USD. Seagen's net margin stands at -32.6%, down from -6.9% several years earlier.
Seagen stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Seagen business model & stock analysis
Frequently asked questions about Seagen
Seagen Inc, formerly known as Seattle Genetics, operates under a unique business model focused on biotechnology. The company specializes in developing and commercializing innovative antibody-based therapies to treat cancer. By harnessing the power of antibody-drug conjugates (ADCs), Seagen Inc aims to deliver targeted treatments directly to cancer cells while minimizing damage to healthy cells. This approach allows for more effective and precise treatment options, potentially improving patient outcomes. Seagen Inc's commitment to research, development, and collaboration with partners worldwide demonstrates their dedication to advancing cancer care and providing hope for patients globally.
Seagen Inc is primarily active in the biotechnology industry.
The main competitors of Seagen Inc in the market include companies such as Genmab, AstraZeneca, and Roche.
Seagen Inc, formerly known as Seattle Genetics, is a biotechnology company based in Bothell, Washington. Established in 1997, Seagen focuses on the development and commercialization of innovative therapies for cancer treatment. The company has been at the forefront of antibody-drug conjugate (ADC) technology, which enables targeted delivery of potent drugs to cancer cells. Seagen's flagship product, ADCETRIS® (brentuximab vedotin), has gained significant recognition as a targeted therapy for Hodgkin lymphoma and certain types of non-Hodgkin lymphoma. With a commitment to advancing breakthrough therapies, Seagen continues to pave the way in the field of oncology.
Seagen Inc, a renowned biotechnology company, has achieved numerous significant milestones. Notably, the company received the US Food and Drug Administration (FDA) approval for its groundbreaking antibody-drug conjugate, ADCETRIS®. This therapeutic innovation has revolutionized the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Seagen Inc has also successfully introduced EVOTEC and SGEN-001, expanding its product portfolio and advancing the fight against cancer. The company's commitment to research and development has resulted in crucial advancements and collaborations, consolidating its position as a leader in the biopharmaceutical industry. Seagen Inc's relentless pursuit of innovative solutions continues to make a substantial impact in transforming patients' lives.
Seagen Inc, a leading biotechnology company, is primarily present in multiple countries and regions across the world. With its headquarters in the United States, Seagen Inc has a significant presence in North America, including the United States and Canada. Additionally, the company extends its operations and reach to various European countries, such as Germany, France, Italy, Spain, and the United Kingdom. Seagen Inc also has a presence in Asia, with a focus on Japan. Through its global presence, Seagen Inc is dedicated to advancing innovative therapies and improving patient outcomes worldwide.
Seagen Inc represents a set of core values and a corporate philosophy that drive its operations. The company places great emphasis on advancing science to develop innovative targeted therapies for patients facing cancer. With a focus on precision medicine, Seagen Inc strives to provide therapies that address significant unmet medical needs. By collaborating with partners, the company aims to advance its mission to make a meaningful difference in the lives of cancer patients. Seagen Inc's dedication to scientific excellence, patient-centricity, and collaboration forms the foundation of its corporate philosophy and guides its pursuit of breakthrough treatments in the field of oncology.
23 analysts currently rate the Seagen stock: 9 recommend buying, 14 holding and 0 selling. For 2026, analysts expect Seagen to generate revenue of 5.33 B USD and earnings per share of 3.70 USD.
Converted at the current exchange rate, the Seagen share trades at 205.23 EUR (228.74 USD).
The Seagen share (SGEN) is listed on 5 stock exchanges, including: NASDAQ (SGEN), London (0A8R.L), SIX (Zürich) (SGT.SW), Frankfurt (SGT.F), München (SGT.MU).
Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. The company was founded in 1998 and is headquartered in Seattle, USA. Seagen offers a wide range of products and services based on antibodies that can be used for the treatment of cancer and other serious diseases. The company operates in two main divisions: the commercial division and the clinical research and development division. The commercial division of Seagen currently distributes several approved products and therapies, including: - Adcetris: an antibody-drug conjugate (ADC) used for the treatment of lymphoma and Hodgkin's cancer. - Tukysa: an oral medication for the treatment of HER2-positive breast cancer. - Padcev: an ADC used for the treatment of bladder cancer. - Enfortumab Vedotin: an ADC used for the treatment of advanced urothelial carcinoma. - Seattle Genetics: a platform consisting of multiple antibody technologies used for the production of ADCs. Seagen's clinical research division is highly interested in developing new and innovative therapies for cancer and autoimmune diseases. One important area of research is new ADC products and antibody technologies that can help target cancer cells. Seagen pursues a comprehensive business model that includes the sale of new products and therapies, as well as collaborations with various pharmaceutical and biotech companies in the development of new technologies and therapies. The company has also entered into research collaborations with other companies and institutions to accelerate the discovery of new ADCs and other treatment options. In addition, Seagen also offers a range of services in the field of clinical studies, including planning, conducting, and analyzing studies. These services are offered to pharmaceutical and biotech companies developing their own products and technologies. Overall, Seagen aims to further expand its position as a leading provider of antibody-based therapies and products for cancer and autoimmune diseases. The company is committed to offering its customers and partners the best solutions and services to improve the treatment of patients worldwide. Answer: Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. It offers a wide range of products and services for the treatment of cancer and other serious diseases, including antibody-drug conjugates (ADCs) such as Adcetris, Tukysa, Padcev, and Enfortumab Vedotin. Seagen is dedicated to developing new and innovative therapies, particularly in the field of ADC products and antibody technologies. The company operates in both commercial and clinical research divisions and collaborates with other organizations to accelerate the discovery of new treatment options. Additionally, Seagen provides services for clinical studies and aims to be a leading provider of antibody-based therapies worldwide.
The expected revenue of Seagen is 5.33 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Seagen is 695.98 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Seagen is currently 61.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Seagen stock.
The price-to-sales ratio (P/S) of Seagen is currently 8.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Seagen stock.
The Eulerpool Quality Score for Seagen is 2/10.
The ISIN of Seagen is US81181C1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Seagen is 602322. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Seagen is SGEN. The ticker symbol is used to trade Seagen shares on the stock exchange.
Seagen stock
Seagen Ticker
Seagen FIGI
All fundamentals and in-depth analysis of Seagen
Our stock analysis for Seagen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seagen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.